Abstract Details

Title Burden of Spasticity Among Patients and Caregivers: Results of a Multinational Survey

Topic Neuro-rehabilitation

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-019

Objective To present results from a multinational survey relating to the self-reported impact of spasticity on patients and caregivers.

Background The impact of spasticity on activities of daily living, quality of life (QoL) and employment from the perspective of patients and caregivers has not been widely reported.

Design/Methods Members of an online community for people with chronic health conditions (Carenity) from France, Germany, Italy, Spain, the UK and the US, were invited by email to participate in an internet-based survey from November 2017 to February 2018. Patients and caregivers of patients (≥18 years old) who had received botulinum toxin type A (BoNT-A) for ≥1 year to treat spasticity due to: multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, cerebral palsy, brain tumor or spastic paraplegia, were eligible to complete the questionnaire, which comprised multiple choice, Likert scale or free text answers.

Results The survey had 615 respondents (427 patients; 188 caregivers). Difficulties in daily living due to spasticity were reported by 98% of respondents, which included carrying objects (98%), walking (97%), performing daily tasks (97%) and driving (96%). Mean impact scores were highest for professional life (7.4/10), sexual life (7.2/10) and QoL (7.2/10). Professional status was affected for respondents aged <65 years, with 31% of employed patients working part-time due to spasticity and 29% of caregivers employed part-time or unemployed in order to care for patients. Additionally, 78% of working patients and 84% of caregivers required time off from work for BoNT-A treatment, resulting in a reduced salary.

Conclusions

Spasticity has a substantial burden on patients and caregivers significantly affecting their overall QoL. The burden of spasticity reported in this survey may be improved with BoNT-A treatment, however QoL is not routinely studied in clinical trials of BoNT-A therapy.

This study was sponsored by Ipsen.

Authors/Disclosures
Atul T. Patel PRESENTER	Atul T. Patel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. Atul T. Patel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for IPSEN. Atul T. Patel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Atul T. Patel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. Atul T. Patel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for IPSEN. The institution of Atul T. Patel has received research support from Abbvie. The institution of Atul T. Patel has received research support from IPSEN.
Theodore Wein, MD (Montreal General Hospital)	No disclosure on file
Laxman Bahroo, DO, FAAN (Medstar Georgetown University Hospital)	Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ipsen. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acadia. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. Dr. Bahroo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Acorda. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Amneal. Dr. Bahroo has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Supernus. Dr. Bahroo has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Neurocrine. Dr. Bahroo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lundbeck. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merz.
	No disclosure on file
	No disclosure on file
Manuel Murie	No disclosure on file

��ɫ��

��ɫ��